Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after ...
Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and ...
Zydus Therapeutics Inc. ("Zydus Therapeutics"), a wholly owned subsidiary of Zydus Lifesciences Limited, a global innovation ...
A look at what really drove Moderna's swing to profit, why its cash picture is less impressive than it first looks, and what ...
While Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding ...
A liver drug could be used to slow down the progression of Parkinson's disease as it joins the world's largest trial of ...
Immunic (NASDAQ:IMUX) is preparing a Phase 3 trial of its experimental multiple sclerosis drug vidofludimus calcium in ...
Analysis of paired patient biopsies from the randomized Phase 2 OVATION 2 study shows IMNN-001 increased CD8+/Treg, CD8+/CD4+ ...
Across randomised trials of GLP-1 receptor agonists, pancreatitis has been a rare event: 16 confirmed cases among 14,562 ...
(9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results